Oritavancin, a potent lipoglycopeptide antibiotic, with a convenient single dose
regimen, remains active against methicillin-resistant Staphylococcus aureus (MRSA).
This study assessed the activity of oritavancin and comparators against a
collection of contemporary European isolates.

**Introduction**

- Oritavancin is a lipoglycopeptide antibiotic with an extended spectrum of activity.
- It has a convenient single-dose regimen, making it suitable for treating serious infections.
- Oritavancin has shown activity against methicillin-resistant Staphylococcus aureus (MRSA).
- This study aimed to assess the activity of oritavancin and comparators against a contemporary collection of European isolates.

**Materials and Methods**

- **Organism collection:** A total of 1,232 S. aureus isolates were collected from clinical specimens.
- **Antimicrobial susceptibility testing:** MICs were determined using broth microdilution.
- **Statistical analysis:** Data were analyzed using descriptive statistics.

**Results**

- **A. aureus** was the most frequently recovered from bloodstream infections (77.8%) followed by pneumonia (17.2%).
- **Table 2** shows the MIC distribution of oritavancin and comparator agents against S. aureus isolates.
- **Figure 2** illustrates the activity of oritavancin and comparators against MRSA isolates.
- **Table 3** lists the MIC50 and MIC90 values for oritavancin and comparators against European isolates.

**Conclusions**

- **Oritavancin showed good activity (MIC50/MIC90, 0.03/0.06 mg/L) against the 2017–2018 European collection of S. aureus isolates relevant for pneumonia, bloodstream infections, infections of bone and joint, intra-abdominal, and infections of brain and spinal cords.**
- **Oritavancin was also active against MRSA isolates displaying reduced susceptibility to vancomycin and teicoplanin.**
- **A prolonged half-life and high potency may support oritavancin as a good option for treating serious infections in Europe.**

**Acknowledgements**

Funding for this research was provided by Merck Sharp & Dohme, Montvale, NJ. USA.

**References**

Clinical and Laboratory Standards Institute (2019). **M31-A3P Pdf** Performance standards for antimicrobial susceptibility testing: 30th informational supplement. Wayne, PA; CLSI.


M100Ed29E. Performance standards for antimicrobial susceptibility testing: 29th informational supplement. Wayne, PA: CLSI.

Wayne, PA: CLSI.

**Contact**

Rodrigo G. Mendes, PhD
JMI Laboratories
340 Beaver Dam Road, Suite A
Wayne, PA 19087
Email: rodrigo-mendes@jmilabs.com
Phone: (319) 665-3370

**To obtain a PDF of this poster:** Scan the QR code or visit https://www.jmilabs.com/Contact/20110817/ECMID2018/563588359/563588359.pdf

Changes may apply. No personal information is shared.